Agile Therapeutics, Inc. (AGRX) saw its loss widen to $7.52 million, or $0.26 a share for the quarter ended Mar. 31, 2017. In the previous year period, the company reported a loss of $7.32 million, or $0.27 a share.
The company has not recorded any revenues for the current as well as previous quarter.
Operating loss for the quarter was $7.13 million, compared with an operating loss of $6.98 million in the previous year period.
"During the first quarter, we continued to advance towards our goal of receiving regulatory approval for Twirla, participated in a productive pre-submission meeting with the FDA and continued to prepare our NDA for resubmission. Additionally we have had multiple scientific opportunities to discuss our Phase 3 SECURE trial results at medical conferences. We continue to expect to submit our NDA by the end of the second quarter of 2017," said Al Altomari, chairman and chief executive officer of Agile. "Additionally, we continue to focus on developing our commercialization plans in coordination with the prudent management of our capital resources. We believe that the flexibility built into our business plan can enable us to fund our operations into the second quarter of 2018."
Disclaimer: Please note that this is an auto-generated article. IRIS does not guarantee the accuracy, adequacy or completeness of any information and is not responsible for any errors or omissions or for the results obtained from the use of such information. IRIS especially states that it has no financial liability whatsoever to any user on account of the use of information provided on its website. For queries contact: editor@irisindia.net
